Digital & Innovation

Harnessing the power of artificial intelligence in pathology to detect cancer

Health Industry Hub | March 15, 2021 |
[Total: 1    Average: 4/5]

Digital & Innovation: A large international collaboration, led by University of Sydney, has developed an innovative, advanced artificial intelligence (AI) application, PathoFusion, that could be used for the examination of routine tissue samples in order to identify indications of cancer.

The research melds contributions from computer scientists, neuropathologists, neuosurgeons, medical oncologists and medical imaging scientists.

ANSTO’s Prof Richard Banati, a Professor of Medical Radiation Sciences/Medical Imaging, who studies the brain’s innate immune system using advanced medical imaging techniques, is a co-author on the paper published in the journal, Cancers.

“The idea behind PathoFusion was to create a novel advanced deep learning model to recognise malignant features and immune response markers, independent of human intervention, and map them simultaneously in a digital image,” explained Banati.

The experiment to evaluate the model involved the examination of tissue from cases of glioblastoma, an aggressive cancer that affects the brain or spine.

The team used the expert input of neuropathologists to ‘train’ the software to mark key features.

Experiments confirmed that the application achieved a high level of accuracy in recognising and mapping six typical neuropathological features that are markers of a malignancy.

Pathofusion reliably identified forms and structural features with a precision of 94% and sensitivity of 94.7% and immune markers at a precision of 96.2% and sensitivity of 96.1%.

The application combines layers of information about dead or dying tissue, the proliferation of microscopic blood vessels and other vasculature with the expression of a tumour genetic marker, CD276, in an image that combines the data in a heatmap.

“The research confirmed that it is possible to train neural networks effectively using only a relatively small number of cases, that should be useful for some scenarios,” said Banati.

Painstaking and time-consuming routine morphological diagnostic work is carried out by pathologists, who examine individual slides under a microscope to mark and quantify features that are markers of disease and provide the information to clinicians.

“Anticipating further hardware improvements in computing, it should exceed the speed of human microscopic feature recognition by orders of magnitude when whole histological slides are used at high resolution,”  said Prof Manuel Graeber of the University of Sydney and Brain and Mind Centre. 

“In future, the model could improve the workflow of a neuropathology or pathology unit by facilitating microscopic analyses or benefit patients in area without local access to these services, “ explained Banati.

Contributors to the research included The University of Sydney, The Brain and Mind Centre, Xuanwu  Hospital (China), St Vincent’s Hospital, Cooperative Trials Group of Neuro-Oncology, Brain Cancer Consultancy and University of Western Australia.

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]